Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Atezolizumab + CPI-444|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).|
|CPI-444||Ciforadenant|V81444|CPI 444|CPI444||Adenosine Targeting 18||Ciforadenant (CPI-444) binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29923026, PMID: 30131376).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||Atezolizumab + CPI-444||Phase I||Actionable||In a Phase I trial, treatment with the combination of CPI-444 and Tecentriq (atezolizumab) was well-tolerated and resulted in a disease control rate of 100% (3/3) in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 3004)).||detail...|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Atezolizumab + CPI-444||Phase I||Actionable||In a Phase I trial, treatment with the combination of CPI-444 and Tecentriq (atezolizumab) was well-tolerated and resulted in a disease control rate of 71% (5/7) in patients with non-small cell lung cancer (J Clin Oncol 35, 2017 (suppl; abstr 3004)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02655822||Phase I||Atezolizumab + CPI-444 CPI-444||Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers||Recruiting|
|NCT03337698||Phase Ib/II||Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688||A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung)||Recruiting|